Sense about Science ? equipping people to make sense of science and evidence
Friday, 13 February 2015: 5:30 PM - 7:00 PM
ZERO1 Gallery, 439 S 1st St, San Jose (opposite the San Jose Convention Centre)
This event will introduce the recently established Sense About Science USA to an invited audience, with discussion of its collaboration with Stats.org and plans for the Ask for Evidence campaign in the US.
Professor John Ioannidis, C.F. Rehnborg Chair in Disease Prevention at Stanford University, will give a keynote speech to the invited audience, and the evening will feature talks from Brad Fenwick, Senior Vice President of Global Strategic Alliances at Elsevier, Tracey Brown, Director, Sense About Science UK, and Trevor Butterworth, Director, Sense About Science USA.
To attend this event please RSVP to Neda Afsarmanesh: email@example.com
Follow the event on Twitter #AskforEvidence @Senseaboutsci
Saturday, 14 February 2015: 10:00 AM -11:30 AM
Room LL21A (San Jose Convention Center)
The Nigerian government halted polio vaccination after pressure from religious leaders in 2007, and vaccinators continue to be attacked. In South Africa, current president Jacob Zuma publicly expressed the belief that showering after sex prevents HIV transmission. In Zambia, genetically-modified food aid was rejected because of misleading safety claims from the British Medical Association. And traditional medicine remains largely unchallenged across Africa. This session will explore how new ways of organizing and accessing data can connect African science to African decision-makers and help prevent misinformation and manipulation. The rapid development of many African economies is creating an urgent need -- and opportunity -- for sound science and research evidence. Information reaching African decision-makers from companies and development agencies is largely unregulated. The role of academic science in government and the media is not yet strong enough to interrogate claims and prevent misinformation. New information technology is helping Africans take advantage of economic opportunities, from the hugely successful M-Pesa mobile payments and loans service, to online trading platforms such as the African Food Exchange. Can African scientific institutes take advantage of these new platforms? How can they bridge the gap between the growing information base and the public to help prevent misinformation and aid Africa’s development?
Tracey Brown, Sense About Science
Ylann Schemm, Elsevier
Yona Baguma, National Agricultural Research Organization
Nick Ishmael Perkins, SciDev.net Encouraging Science in the Developing World Through Access to Information
Thandi Mgwebi, South African National Research Foundation Developing Institutional Research Capabilities in Africa
Daniel Otunge, African Agricultural Technology Foundation Encouraging Open Discussion on Agricultural Biotechnology in Africa
More information: https://aaas.confex.com/aaas/2015/webprogram/Session9580.html
This session is being co-organised with Cornell Alliance for Science.
Follow the discussion on Twitter, #AfricaExperts @Senseaboutsci
Sunday, 15 February 2015: 1:00 PM -2:30 PM
Room LL21A (San Jose Convention Center)
The amount of publicly available information from clinical trials is increasing rapidly and going to continue to increase. The new European Union Clinical Trials law will require all future drug trials to be registered on a public register and to report results. The recently launched AllTrials campaign, calling for all clinical trials to be registered and results reported, has prompted government bodies and research funders to implement measures to address this. Some pharmaceutical companies have committed to publishing individual patient data from past trials. Challenges are posed by greater clinical trial transparency and availability of information. Clinical trials are being registered on one (or more) of dozens of global registers. Trial data are held in company and institutional repositories. Documents relating to trials -- protocols, regulatory summaries of results, clinical study reports, consent forms, and patient information sheets -- are scattered in different places. It is difficult to track the information that is available, in order to audit for gaps in information and for doctors and regulators to be sure they have all the information they need to make decisions about medicines. There is an unprecedented opportunity to refine how clinical trial data are shared and linked. Experts in this session will discuss the strengths and weaknesses of current registers and new approaches being taken by industry and will introduce AllTrials.org, a new linked and indexed database of all clinical trial information.
Sile Lane, Sense About Science
Frank W Rockhold, GlaxoSmithKline
Deborah Zarin, National Institutes of Health, ClincalTrials.gov - Challenges and Opportunities for the World's Largest Clinical Trials Database
Giorgio Ascoli, George Mason University - Perspective on Neuroscience Data Sharing from NeuroMorpho.Org
Anita de Waard, Elsevier - Bridging the Gap Between Small and Large Research Repositories
Follow the discussion on Twitter, #AllTrials @Senseaboutsci